Paul L. Skipper, John D. Groopman

• The direct determination of human carcinogens and assessment of low-level risks. Molecular epidemiology: overview of biochemical and molecular basis. Interindividual variation in biotransformation of carcinogens: basis and relevance. Validation of molecular epidemiologic methods. . Toxic exposures in a community setting: the epidemiologic approach. Monitoring of in vivo dose by macromolecular adducts: usefulness in risk estimation. Human tissue culture systems for studies of carcinogen metabolism and macromolecular interactions. 32p-postlabeling analysis of mutagen- and carcinogen-dna adducts and age-related dna modifications (i compounds). DNA-adduct analysis by 32p-postlabeling in the study of human exposure to carcinogens. Quantitative analysis of dna adducts: the potential for mass spectrometric techniques. Analytical approaches for the determination of protein-carcinogen adducts using mass spectrometry. Development of immunoassays for the detection of carcinogen-dna adducts. Immunoassays for the clinically used dna-damaging agents 8-methoxypsoralen and cis-diamminedichloroplatinum (ii). Application of fluorescence to analysis of genotoxicity. Detection of alkylated dna adducts in human tissues. Noninvasive methods for measuring exposure to alkylating agents: recent studies on human subjects. Molecular dosimetry of human aflatoxin exposures. Monitoring exposure to tobacco products by measurement of nicotine metabolites and derived carcinogens. Exposure control versus risk assessment: lessons from the study of genotoxic n-substituted arenes. The bioethics of biomonitoring people for exposure to carcinogens. Genetic testing in the workplace: costs and benefits. Medical screening for carcinogenesis: legal and ethical considerations.